[go: up one dir, main page]

WO2008102452A1 - Ｈｇｆ製剤 - Google Patents

Ｈｇｆ製剤 Download PDF

Info

Publication number
WO2008102452A1
WO2008102452A1 PCT/JP2007/053316 JP2007053316W WO2008102452A1 WO 2008102452 A1 WO2008102452 A1 WO 2008102452A1 JP 2007053316 W JP2007053316 W JP 2007053316W WO 2008102452 A1 WO2008102452 A1 WO 2008102452A1
Authority
WO
WIPO (PCT)
Prior art keywords
hgf
hgf preparation
preparations
preparation
characteristic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/053316
Other languages
English (en)
French (fr)
Inventor
Kiichi Adachi
Keigo Hanada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kringle Pharma Inc
Original Assignee
Kringle Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kringle Pharma Inc filed Critical Kringle Pharma Inc
Priority to PCT/JP2007/053316 priority Critical patent/WO2008102452A1/ja
Priority to CN2013102442581A priority patent/CN103356995A/zh
Priority to CNA2008800016430A priority patent/CN101578106A/zh
Priority to PCT/JP2008/052979 priority patent/WO2008102849A1/ja
Priority to CA2675622A priority patent/CA2675622C/en
Priority to EP08711762.8A priority patent/EP2119449B1/en
Priority to JP2009500236A priority patent/JP5265514B2/ja
Priority to KR1020097016540A priority patent/KR101492511B1/ko
Publication of WO2008102452A1 publication Critical patent/WO2008102452A1/ja
Priority to US12/432,651 priority patent/US8461112B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　本発明はＨＧＦおよび精製白糖を含有するＨＧＦ製剤である。本ＨＧＦ製剤は長期間の保存でも安定であるという特長を有する。
PCT/JP2007/053316 2007-02-22 2007-02-22 Ｈｇｆ製剤 Ceased WO2008102452A1 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PCT/JP2007/053316 WO2008102452A1 (ja) 2007-02-22 2007-02-22 Ｈｇｆ製剤
EP08711762.8A EP2119449B1 (en) 2007-02-22 2008-02-21 Hgf preparation
CNA2008800016430A CN101578106A (zh) 2007-02-22 2008-02-21 Hgf制剂
PCT/JP2008/052979 WO2008102849A1 (ja) 2007-02-22 2008-02-21 Ｈｇｆ製剤
CA2675622A CA2675622C (en) 2007-02-22 2008-02-21 Hgf preparation
CN2013102442581A CN103356995A (zh) 2007-02-22 2008-02-21 Hgf制剂
JP2009500236A JP5265514B2 (ja) 2007-02-22 2008-02-21 Ｈｇｆ製剤
KR1020097016540A KR101492511B1 (ko) 2007-02-22 2008-02-21 Ｈｇｆ 제제
US12/432,651 US8461112B2 (en) 2007-02-22 2009-04-29 HGF preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2007/053316 WO2008102452A1 (ja) 2007-02-22 2007-02-22 Ｈｇｆ製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/053316 Continuation-In-Part WO2008102452A1 (ja) 2007-02-22 2007-02-22 Ｈｇｆ製剤

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/JP2007/053316 Continuation-In-Part WO2008102452A1 (ja) 2007-02-22 2007-02-22 Ｈｇｆ製剤
PCT/JP2008/052979 Continuation-In-Part WO2008102849A1 (ja) 2007-02-22 2008-02-21 Ｈｇｆ製剤
PCT/JP2008/052979 Continuation WO2008102849A1 (ja) 2007-02-22 2008-02-21 Ｈｇｆ製剤

Publications (1)

Publication Number Publication Date
WO2008102452A1 true WO2008102452A1 (ja) 2008-08-28

Family

ID=39709738

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2007/053316 Ceased WO2008102452A1 (ja) 2007-02-22 2007-02-22 Ｈｇｆ製剤
PCT/JP2008/052979 Ceased WO2008102849A1 (ja) 2007-02-22 2008-02-21 Ｈｇｆ製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052979 Ceased WO2008102849A1 (ja) 2007-02-22 2008-02-21 Ｈｇｆ製剤

Country Status (6)

Country Link
US (1) US8461112B2 (ja)
EP (1) EP2119449B1 (ja)
KR (1) KR101492511B1 (ja)
CN (2) CN103356995A (ja)
CA (1) CA2675622C (ja)
WO (2) WO2008102452A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE039967T2 (hu) 2009-11-23 2019-02-28 Cubist Pharmaceuticals Llc Lipopeptid kompozíció és ezzel kapcsolatos eljárások
JP6426410B2 (ja) * 2013-09-11 2018-11-21 第一三共株式会社 室温保存用凍結乾燥製剤
TWI728409B (zh) * 2014-04-28 2021-05-21 日商衛材R&D企管股份有限公司 Hgf冷凍乾燥製劑
EP3192524B1 (en) 2014-09-10 2021-12-29 Kringle Pharma Inc. Hgf preparation suitable for treatment of neurological disorders
AU2017232582B2 (en) 2016-03-17 2022-07-14 Eisai R&D Management Co., Ltd. Method for producing activated hepatocyte growth factor (HGF)
WO2021183752A1 (en) 2020-03-12 2021-09-16 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
JP7750489B2 (ja) 2020-04-20 2025-10-07 塩野義製薬株式会社 Ｈｍｇｂ１部分ペプチドを含有する製剤
BR112023022474A2 (pt) 2021-05-14 2024-01-09 Claris Biotherapeutics Inc Composições de fator de crescimento para o tratamento de doença ocular

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6289628A (ja) * 1985-09-11 1987-04-24 Green Cross Corp:The 人フイブリノゲン製剤の加熱処理法
JPH0925241A (ja) * 1995-07-11 1997-01-28 Snow Brand Milk Prod Co Ltd Ｈｇｆ凍結乾燥製剤
CN1579544A (zh) * 2003-08-09 2005-02-16 杨喜鸿 促肝细胞生长素口含片

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
ATE372127T1 (de) 1997-12-03 2007-09-15 Nakamura Toshikazu Präparation zur kontinuierlichen intravenösen verabreichung
CN1222310C (zh) 1998-08-05 2005-10-12 住友制药株式会社 肝实质细胞增殖因子药用制剂
US6896609B2 (en) * 2003-07-22 2005-05-24 International Truck Intellectual Property Company, Llc Driver/entry ventilation system for a bus
CN1554338A (zh) * 2003-12-23 2004-12-15 南京易川药物研究所 亚硫酸氢钠穿心莲内酯冻干制剂及其制备方法
EP1719521A1 (en) * 2004-01-30 2006-11-08 Mitsubishi Pharma Corporation Preventive and/or remedy for retinopathy
BRPI0512482A (pt) * 2004-07-26 2008-03-11 Genentech Inc método de identificação de uma substáncia inibidora candidata e molécula antagonista
KR20080082629A (ko) * 2005-11-10 2008-09-11 리셉터 바이오로직스 인크 간세포 성장인자 인트론 융합 단백질

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6289628A (ja) * 1985-09-11 1987-04-24 Green Cross Corp:The 人フイブリノゲン製剤の加熱処理法
JPH0925241A (ja) * 1995-07-11 1997-01-28 Snow Brand Milk Prod Co Ltd Ｈｇｆ凍結乾燥製剤
CN1579544A (zh) * 2003-08-09 2005-02-16 杨喜鸿 促肝细胞生长素口含片

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARAKAWA R.: "Toketsu Sosa ni Oite Tenkabutsu ha Donoyoni shite Tanpakushitsu o Anteika suru noka", PROTEIN, NUCLEIC ACID AND ENZYME, vol. 37, no. 9, 1992, pages 1517 - 1523, XP003024526 *

Also Published As

Publication number Publication date
CA2675622A1 (en) 2008-08-28
KR101492511B1 (ko) 2015-02-12
CA2675622C (en) 2015-10-06
US8461112B2 (en) 2013-06-11
EP2119449A4 (en) 2013-05-08
EP2119449B1 (en) 2014-09-03
CN101578106A (zh) 2009-11-11
EP2119449A1 (en) 2009-11-18
WO2008102849A1 (ja) 2008-08-28
KR20090118030A (ko) 2009-11-17
US20090233863A1 (en) 2009-09-17
CN103356995A (zh) 2013-10-23

Similar Documents

Publication Publication Date Title
WO2008102452A1 (ja) Ｈｇｆ製剤
WO2009100102A3 (en) Ts23 alpha-amylase variants with altered properties
WO2007124090A3 (en) Lyophilized therapeutic peptibody formulations
IL204621A0 (en) Bicyclic - ?? - amino acid derivatives, compositions comprising the same and uses thereof
WO2009039951A3 (de) Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften
WO2010065969A8 (en) Sparc binding scfcs
WO2007086001A3 (en) Novel pyridine derivatives
IL201009A (en) Pyrazolo pyridine derivatives, preparations containing them and their uses
EP2165694B8 (en) Vesicle useful for external preparation for skin, and external preparation for skin comprising the vesicle
WO2007008384A3 (en) Food articles with delivery devices and methods for the preparation thereof
EP2136638A4 (en) MODIFIED RELEASE FORMULATIONS OF (6R) -4,5,6,7-TETRAHYDRO-N6-PROPYL-2,6-BENZOTHIAZOLE DIAMINE AND METHODS OF USE THEREOF
IL200407A (en) Stable digestive enzyme preparations, methods of preparation and use thereof
IL211892A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
IL213613A0 (en) Pyrazine derivatives, compositions comprising the same and uses thereof
IL211890A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
IL211889A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
IL195528A (en) Pyridazine compound, methods of preparation, a pharmaceutical composition containing it, its use and intermediate material
WO2007076027A3 (en) Novel formulations of bifenthrin and enriched cypermethrin
IL211891B (en) Pyrazolo pyridine derivatives, preparations containing them and their uses
EP2180024A4 (en) HYDROPHILIC FILM-FORMING COMPOSITION, SPRAYING COMPOSITION AND HYDROPHILIC ELEMENT THEREWITH
WO2010046061A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
WO2006096518A3 (en) Improved gacyclidine formulations
WO2006050341A3 (en) Modified streptococcal polysaccharides and uses thereof
WO2008116610A8 (en) Flame retarded polyurethane foam formulations with low smoke performance

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07714813

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07714813

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP